| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | GDC-0449 | FIMM | pan-cancer | AAC | -0.18 | 0.3 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.3 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |